Search Results

There are 235632 results for: content related to: Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response

  1. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients

    Intervention Review

    The Cochrane Library

    Lior H Katz, Hadar Goldvaser, Anat Gafter-Gvili and Ran Tur-Kaspa

    Published Online : 12 SEP 2012, DOI: 10.1002/14651858.CD008516.pub2

  2. You have full text access to this OnlineOpen article
    Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders

    Hepatology

    Volume 46, Issue 6, December 2007, Pages: 1688–1694, Brian L. Pearlman, Carole Ehleben and Sophia Saifee

    Article first published online : 28 NOV 2007, DOI: 10.1002/hep.21919

  3. You have full text access to this OnlineOpen article
    Reply:

    Hepatology

    Volume 52, Issue 4, October 2010, Pages: 1520–1521, Maria Buti and Rafael Esteban

    Article first published online : 28 SEP 2010, DOI: 10.1002/hep.23951

  4. You have full text access to this OnlineOpen article
    Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

    Hepatology

    Volume 52, Issue 4, October 2010, Pages: 1201–1207, Maria Buti, Yoav Lurie, Natalia G. Zakharova, Natalia P. Blokhina, Andrzej Horban, Gerlinde Teuber, Christoph Sarrazin, Ligita Balciuniene, Saya V. Feinman, Rab Faruqi, Lisa D. Pedicone and Rafael Esteban

    Article first published online : 30 JUN 2010, DOI: 10.1002/hep.23816

  5. You have full text access to this OnlineOpen article
    Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future

    Hepatology

    Volume 54, Issue 3, 2 September 2011, Pages: 789–800, Vincent Di Martino, Carine Richou, Jean-Paul Cervoni, Jose M. Sanchez-Tapias, Donald M. Jensen, Alessandra Mangia, Maria Buti, Frances Sheppard, Peter Ferenci and Thierry Thévenot

    Article first published online : 19 JUL 2011, DOI: 10.1002/hep.24480

  6. You have full text access to this OnlineOpen article
    Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin

    Hepatology

    Volume 54, Issue 5, November 2011, Pages: 1518–1526, Thomas-Matthias Scherzer, Albert Friedrich Stättermayer, Michael Strasser, Hermann Laferl, Andreas Maieron, Rudolf Stauber, Christian Datz, Emina Dulic-Lakovic, Petra Steindl-Munda, Harald Hofer and Peter Ferenci

    Article first published online : 28 OCT 2011, DOI: 10.1002/hep.24546

  7. You have full text access to this OnlineOpen article
    Effect of interleukin-28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with pegylated interferon alpha-2a/ribavirin

    Hepatology

    Volume 55, Issue 5, May 2012, Page: 1645, Brian L. Pearlman and Carole Ehleben

    Article first published online : 19 APR 2012, DOI: 10.1002/hep.25552

  8. You have full text access to this OnlineOpen article
    Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin

    Journal of Viral Hepatitis

    Volume 19, Issue 2, February 2012, Pages: 94–102, N. Reau, F. M. Hamzeh, E. Lentz, X. Zhou and D. Jensen

    Article first published online : 12 JAN 2011, DOI: 10.1111/j.1365-2893.2010.01422.x

  9. Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin

    Journal of Viral Hepatitis

    Volume 18, Issue 4, April 2011, Pages: e99–e103, M. Parikh, A. Singh and G. Sood

    Article first published online : 18 OCT 2010, DOI: 10.1111/j.1365-2893.2010.01374.x

  10. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials

    International Journal of Clinical Practice

    Volume 66, Issue 4, April 2012, Pages: 342–355, L. Y. Lee, C. Y.W. Tong, T. Wong and M. Wilkinson

    Article first published online : 15 MAR 2012, DOI: 10.1111/j.1742-1241.2012.02895.x

  11. You have full text access to this OnlineOpen article
    Abstracts 259 to 542

    Hepatology

    Volume 44, Issue S1, October 2006, Pages: 287A–390A,

    Article first published online : 25 SEP 2006, DOI: 10.1002/hep.21396

  12. You have full text access to this OnlineOpen article
    Idiopathic thrombocytopenic purpura after colectomy for pediatric ulcerative colitis

    Inflammatory Bowel Diseases

    Volume 14, Issue 9, September 2008, Pages: 1313–1315, Sharon Yong, Rabin Persad, Nancy Dower, Gordon Lees and Wael El-Matary

    Article first published online : 14 MAR 2008, DOI: 10.1002/ibd.20439

  13. Economic impact of extended treatment with peginterferon α-2a and ribavirin for slow hepatitis C virologic responders

    Journal of Viral Hepatitis

    Volume 15, Issue 4, April 2008, Pages: 293–299, J. Nakamura, S.-I. Toyabe, Y. Aoyagi and K. Akazawa

    Article first published online : 9 DEC 2007, DOI: 10.1111/j.1365-2893.2007.00943.x

  14. Optimal treatment duration for patients with HCV genotype 1 infection

    Journal of Viral Hepatitis

    Volume 19, Issue s1, January 2012, Pages: 7–13, P. Ferenci

    Article first published online : 10 JAN 2012, DOI: 10.1111/j.1365-2893.2011.01522.x

  15. Benefit of microwave-assisted acid hydrolysis of proteins for mass spectrometric profiling of the human heart tissue proteome

    Rapid Communications in Mass Spectrometry

    Volume 21, Issue 16, 30 August 2007, Pages: 2779–2783, Mulu Gebremedhin, Hongying Zhong, Shaohua Wang, Michael Weinfeld and Liang Li

    Article first published online : 24 JUL 2007, DOI: 10.1002/rcm.3125

  16. Megacolon in multiple system atrophy: Safety concerns related to PEG

    Movement Disorders

    Volume 24, Issue 7, 15 May 2009, Pages: 1096–1097, Toshiyuki Tezuka, Tetsutaro Ozawa, Yuhei Takado, Yuichi Sato, Mutsuo Oyake and Masatoyo Nishizawa

    Article first published online : 25 FEB 2009, DOI: 10.1002/mds.22281

  17. You have full text access to this OnlineOpen article
    Abstracts 210 to 431

    Hepatology

    Volume 46, Issue S1, October 2007, Pages: 331A–430A,

    Article first published online : 19 SEP 2007, DOI: 10.1002/hep.22017

  18. An autopsy case of dementia with Lewy bodies showing autonomic failure and dementia as the initial symptoms

    Movement Disorders

    Volume 22, Issue 8, 15 June 2007, Pages: 1212–1213, Masato Kanazawa, Kazuhiro Sanpei, Yasuko Toyoshima, Izumi Kawachi, Yoshiaki Honma and Hitoshi Takahashi

    Article first published online : 7 MAY 2007, DOI: 10.1002/mds.21523

  19. You have free access to this content
    Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders

    Alimentary Pharmacology & Therapeutics

    Volume 30, Issue 4, August 2009, Pages: 343–351, M. NAGAKI, M. SHIMIZU, J. I. SUGIHARA, E. TOMITA, C. SANO, T. NAIKI, K. KIMURA, K. AMANO, T. SAKAI, M. NINOMIYA, T. KOJIMA, N. KATSUMURA, M. FUJIMOTO and H. MORIWAKI

    Article first published online : 26 MAY 2009, DOI: 10.1111/j.1365-2036.2009.04048.x

  20. HCV Genotype 1: How are you Managing the Non-Responders and Relapsers? A North American Perspective

    Clinical Dilemmas in Viral Liver Disease

    Graham R. Foster, K. Rajender Reddy, Pages: 38–42, 2010

    Published Online : 10 MAR 2010, DOI: 10.1002/9781444319590.ch8